#1 - Hilton (NYSE:HLT)
If you were going to invest in hotels right now, many investors would say to look to buy shares of a real estate investment trust that specialized in hotel chains. Or, you could buy Hilton (NYSE:HLT) stock. It’s maybe not the same thing. However, one thing that made Hilton different from many hotel chains was that it lent its name and branding to properties and then operated as a REIT.
This was a profitable model for the company until the pandemic set in and those franchises had difficulty paying the rent. Fortunately, Hilton did have revenue coming in on the properties that it continues to own outright.
Through three quarters, Hilton is reporting just $3.4 billion in earnings which will leave the company well shy of the $9.45 billion it drew in 2019. Still, the company has ample cash and is seeing its stock price close in on its pre-pandemic level. Analysts are also warming up to HLT stock and have it as a consensus buy.
About Hilton Worldwide
Hilton Worldwide Holdings Inc, a hospitality company, engages in managing, franchising, owning, and leasing hotels and resorts. It operates through two segments, Management and Franchise, and Ownership. The company engages in the hotel management and licensing of its brands. It operates luxury hotels under the Waldorf Astoria Hotels & Resorts, LXR Hotels & Resorts, and Conrad Hotels & Resorts brand; lifestyle hotels under the Canopy by Hilton, Curio Collection by Hilton, Tapestry Collection by Hilton, Tempo by Hilton, and Motto by Hilton brand; full service hotels under the Signia by Hilton, Hilton Hotels & Resorts, and DoubleTree by Hilton brand; service hotels under the Hilton Garden Inn, Hampton by Hilton, and Tru by Hilton brand; all-suite hotels under the Embassy Suites by Hilton, Homewood Suites by Hilton, and Home2 Suites by Hilton brand; and economy hotel under the Spark by Hilton brand, as well as Hilton Grand Vacations.
Read More - Current Price
- $251.11
- Consensus Rating
- Hold
- Ratings Breakdown
- 8 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $228.71 (8.9% Downside)
